Modexa Mechanism of Action

Pharmacology: Pharmacodynamics: Mometasone furoate is a topical glucocorticosteroid with local anti-inflammatory properties at doses that are not systemically active.
The precise mechanism of action is unknown, but it is likely that much of the mechanism for the antiallergic and anti-inflammatory effects of mometasone furoate lies in its ability to inhibit the release of mediators of allergic reactions. Mometasone furoate significantly inhibits the release of leukotrienes from leucocytes of allergic patients. In cell culture, mometasone furoate demonstrated high potency in the inhibition of synthesis and release of IL-1, IL-5, IL-6 and TNF-α. It is also a potent inhibitor of the Th₂ cytokines, IL-4, and IL-5, from human CD4+ T-cells. In mixed leukocytes from atopic patients, mometasone furoate was a more potent inhibitor of leukotriene production than beclomethasone dipropionate (BDP). Mometasone furoate has been shown to reduce the accumulation of eosinophils markedly at the site of an allergic reaction. Additionally, mometasone furoate reduced the number of lymphocytes and the levels of messenger RNA for the proallergic cytokines IL-4 and IL-5.
Pharmacokinetics: Mometasone furoate monohydrate, administered as an aqueous nasal spray, has a systemic bioavailability of <1% in plasma. Mometasone furoate nasal spray suspension is very poorly absorbed from the gastrointestinal tract, and the small amount that may be swallowed and absorbed undergoes extensive first-pass hepatic metabolism prior to excretion in urine and bile.